KREMERS URBAN Pharmaceuticals

Published Online: Friday, July 11, 2014
Follow Pharmacy_Times:


Getting pharmaceutical products to market is hard enough. Challenges such as active pharmaceutical ingredient (API), formulation, drug delivery technologies, and manufacturing difficulties can make the task seem even more insurmountable. KREMERS URBAN Pharmaceuticals is a company that delivers the product solutions and dedicated customer service needed to get specialty generic products to market without all the perplexity.

Providing Leadership Through the Drug Development Maze
Many promising drugs are abandoned early because of difficult-to-synthesize ingredients, complicated formulations, manufacturing issues, or legal challenges. KREMERS URBAN Pharmaceuticals, a subsidiary of Belgium-based UCB, strives to deliver the tough solutions and reliable service that get products to market. The company’s focus is providing a wide array of generic pharmaceuticals — particularly products with difficult-to-produce or limited-supply APIs or finished goods formulations, dedicated containment facilities, or Paragraph IV challenges. It is a strategy that is achieved through a combination of internal development and strategic partnerships.

The vision of KREMERS URBAN is to be a premier specialty generic pharmaceutical company with a portfolio of high-barrier-to-entry products and limited competition. Leveraging the vast resources of its parent company, KREMERS URBAN is moving to the forefront of delivering the tough solutions necessary to get complex products into the market. Its professionals are experts at increasing efficiencies and reducing the cost of getting generic products to the appropriate market segments.

A Growing Portfolio of Specialty Generics
The KREMERS URBAN product portfolio has continued to expand and now includes 19 products and 83 SKUs. The newest additions to the KREMERS URBAN product portfolio are Rabeprazole Sodium Delayed-Release Tablets and Methylphenidate HCl Extended-Release Tablets, USP CII 36 mg and 54 mg. The KREMERS URBAN portfolio also provides several difficult-to-manufacture and extended-release products that require complex drug development technology and manufacturing processes, including Atorvastatin Calcium Tablets, Hydrocodone Polistirex and Chlorpheniramine Polistirex Pennkinetic® Extended-Release Suspension CIII, Methylphenidate HCI Extended-Release Capsules CD CII, Pantoprazole Sodium Delayed-Release Tablets USP, Oxybutynin Chloride Extended-Release Tablets USP, Omeprazole Delayed- Release Capsules USP, Nifedipine Extended-Release Tablets USP, Tacrolimus Capsules USP, Verapamil Hydrochloride Extended-Release Capsules (PM), and several other generic products. The company stands behind each of its products, ensuring the highest standards available. In addition to aggressively pursuing in-licensing generic drug products and internal research and development, KREMERS URBAN looks to expand its generic product portfolio by leveraging the biopharmaceutical capabilities being developed by UCB. KREMERS URBAN also seeks strategic alliances in the development of products and drug delivery technologies that would further enhance its capabilities or offerings.

Continuing to Exceed Customer Expectations
KREMERS URBAN continues to make capital investment of more than $8 million annually in the latest technologies to ensure quality and optimize efficiencies. As a result, the KREMERS URBAN manufacturing plant is poised to produce over 3 billion doses by 2016 and approach 4 billion doses over the next 10 years. All this translates to major corporate growth and more extensive capabilities for service levels to continue exceeding customer expectations. Along with commercial offices in Princeton, New Jersey, a dedicated customer service headquarters is located in Seymour, Indiana, where KREMERS URBAN has also established an impressive 400,000 sq ft pharmaceutical manufacturing plant. With its dedicated facilities, comprehensive infrastructure, technical expertise, and UCB corporate support, KREMERS URBAN is uniquely structured and positioned to manage high barriers to entry.

Whether it’s complex APIs, drug delivery systems, or challenging product formulations, you can trust the professionals at KREMERS URBAN to overcome the complications of market entry and SOLVE THE PUZZLE OF SPECIALTY GENERICS.

For more information, visit www.kremersurban.com.

Pennkinetic® is a registered trademark of the UCB Group of companies.

Related Articles
A pharmacist testified before a Senate subcommittee today that unprecedented price hikes for formerly inexpensive generic prescription drugs are “wreaking havoc” on the health care system while jeopardizing the viability of community pharmacies.
Fewer brand-name drugs are prescribed when their generic equivalents are displayed in the electronic health record first.
Generics saved $239 billion in 2013 (a 14% increase in savings from 2012) and more than $1.46 trillion over the recent decade. Further, the Express Scripts 2013 Drug Trend Report issued in 2014 shows that since 2008, the price of brand drugs has almost doubled, but the price of generic drugs has been cut roughly in half.
Latest Issues
$auto_registration$